Saronic Biotechnology

Saronic Biotechnology is a private New York-based biotechnology company developing immunotherapies for liver cancer, particularly hepatocellular carcinoma. Its lead program, SBI1997, is a personalized autologous dendritic cell immunotherapy designed to prime the immune system against tumor-specific antigens and reduce post-surgical recurrence. The company positions itself as focused on adjuvant treatment for liver cancer and has also described earlier-stage discovery efforts in immune cell modulation and molecular-target-based HCC therapeutics. Saronic was founded by physicians and research scientists with expertise in oncology, viral hepatitis, and immunology. Public information suggests the company remains small, private, and centered on a narrow liver-cancer pipeline.